MedPage Today

Common Enzyme Deficiency Linked With COVID Severity

In certain groups of men, glucose-6-phosphate dehydrogenase (G6PD) deficiency was linked with an increased likelihood of severe COVID-19, a Veterans Affairs cohort study found. In Black men under 65, ...
WebMD

Loargys: FDA Approves the First and Only Injectable Enzyme Therapy, Paired With a Low‑Protein Diet, to Lower High Arginine Levels in Patients Ages 2 Years or Older With ...

What Is Loargys, and Why Does It Matter? Loargys is an enzyme-based medicine that has been granted accelerated approval by the FDA for managing high levels of the amino acid arginine (hyperargininemia ...
STAT

In a first, a fatal enzyme deficiency is treated in the womb

To protect this child from the same genetic disease that killed two older siblings, treating her as soon as she was born might only work so well, the doctors knew. So they dialed back the therapeutic ...
MedCity News

Chiesi Wins FDA Approval for First Drug to Treat Ultra-Rare Enzyme Deficiency

A Chiesi Farmaceutici drug for a rare enzyme deficiency is now approved by the FDA, making it the first U.S. treatment for a disorder that leads to a range of cognitive and muscle problems. The ...
Yahoo Finance

U.S. FDA has granted accelerated approval of Loargys® (pegzilarginase-nbln) for the treatment of hyperargininemia in patients 2 years and older with Arginase 1 Deficiency (ARG1-D)

ARG1-D is an ultra-rare, debilitating, and progressive metabolic disease resulting in persistent elevation of plasma arginine, also known as hyperargininemia FDA accelerated approval of LOARGYS is ...